Trafermin
DERMATOLOGICALS
Also known as: CAB-2001, fiblast, KCB-1, trafermin (genetical recombination)
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Trafermin is a drug catalogued in DrugCentral. It was first approved by the PMDA in 2001. Recorded indications include Alveolar bone loss and Perforation of tympanic membrane.
- Indications: Alveolar bone loss and Perforation of tympanic membrane.
- ATC code: D03AX15 (Other cicatrizants).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Alveolar bone loss
- Perforation of tympanic membrane
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2001-04-04 | PMDA | — | Kaken |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
D03AX15 | DERMATOLOGICALS › PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS › CICATRIZANTS › Other cicatrizants |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 131094-16-1 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Trafermin used for?
DrugCentral lists the following indications for Trafermin: Alveolar bone loss and Perforation of tympanic membrane.
When was Trafermin first approved?
Trafermin was first approved by the PMDA in 2001.
Browse: all drugs starting with T · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5219 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2108081 — compound record and bioactivity
- DrugBank DB06244 — drug record
- FDA UNII 333OX80X87 — substance identity
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.